Consequently, some authors have proposed that administration of adiponectin or an adiponectin analog (e.g., osmontin) might be an attractive pharmacological strategy for management of conditions characterized by adiponectin deficiency, such as NAFLD or NASH [8, 41]. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.